The Cigna Group (CI)
Health Care2 articles
Market Mood
Cigna (CI) Downgraded by Barclays, Price Target Cut to $304
On May 26, Barclays downgraded Cigna (CI) from Overweight to Equal Weight and reduced its price target from $310 to $304. The downgrade reflects concerns around Cigna's limited earnings upside potential due to its lower exposure to government insurance programs, alongside uncertainties regarding a pharmacy benefit manager transition. Additionally, Barclays highlighted risks related to commercial membership losses and potential job cuts related to AI. This situation contrasts with UBS's recent rating increase, raising Cigna's target to $400, indicating differing outlooks among analysts.
Read More
Cigna (CI) Q1 2026 Earnings Beat Expectations; Raises EPS Guidance
Cigna (CI) reported its Q1 2026 earnings, exceeding analyst expectations. The company raised its earnings per share (EPS) guidance for the year, indicating stronger financial performance. Cigna's revenue figures and additional growth metrics contributed to the positive outlook, which may influence investor sentiment and market performance. The upward revision of EPS guidance is particularly significant for forecasting future profitability and competitive positioning in the market.
Read More